# US 2019/0314325 A1 · Process and Method to Accelerate Cellular Regeneration, Healing and Wound Management

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314325 A1
- Document ID: US20190314325A1
- Status: Published application
- Kind: A1
- Application number: 16/234,799
- Filed: 2018-12-28
- Published: 2019-10-17
- Earliest claimed: 2018-04-13
- Inventors: Richard Postrel
- Web page: https://patentgrep.com/patent/US20190314325A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/7015: {Drug-containing film-forming compositions, e.g. spray-on}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 36/3482: {Cannabis}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides compositions and methods for cellular regeneration and more rapid healing of surface lesions such as cuts, abrasions, rashes and other skin disturbances. A preferred consumer-based and battlefield embodiment features a spray-on composition delivering at least one substance that stimulates intercellular communication using tunneling nanotubes (TNTs). The induced TNTs increase transport of chemical and/or electrochemical information between more stable and nascent cells or between more intact and damaged cells. The inventive substance is applicable for use for ordinary household type injuries as well as industrial and/or battlefield events, perhaps from physical or chemical accidents or even several types of chemical weapons. Other preferred embodiments incorporate a sealant composition or coating to shield the affected surface area designated for healing from contamination and/or solvents/carriers to facilitate transdermal delivery of one or more pharmaceutically active ingredients.

## Claims

### Claim 1

A treatment composition to accelerate healing of a surface lesion, said treatment composition comprising a topical formulation with at least one or a plurality of components capable of binding and activating at least one endogenous cannabinoid receptor, said activating stimulating tunneling nanotubule intercellular connectivity.

### Claim 2 (depends on 1)

The composition of claim 1 comprising at least one pharmaceutically acceptable organic solvent, at least one polar lipid, at least one surfactant, and at least one compound capable of activating a cannabinoid receptor.

### Claim 3 (depends on 1)

The composition of claim 1 further comprising water wherein the pH of said composition is between about 6.0 and about 8.0.

### Claim 4 (depends on 1)

The composition of claim 1 wherein said polar lipid is selected from the group consisting of: lecithin and phosphatidylcholine.

### Claim 5 (depends on 1)

The composition of claim 1 wherein said pharmaceutically acceptable organic solvent comprises an isopropyl ester.

### Claim 6 (depends on 5)

The composition of claim 5 wherein said isopropyl ester is selected from the group consisting of isopropyl myristate and isopropyl palmitate.

### Claim 7

The composition of claim lfurther comprising urea at a concentration of about 5% to about 20% by mass of the final composition.

### Claim 8 (depends on 4)

The composition of claim 4, wherein said polar lipid comprises lecithin.

### Claim 9 (depends on 2)

The composition of claim 2, wherein said surfactant is selected from the group consisting of docusate sodium, docusate sodium benzoate, docusate calcium, tween 80 and polysorbate 80.

### Claim 10 (depends on 1)

The composition of claim 1, further comprising at least one pharmaceutically active substance selected from the group consisting of: an analgesic substance, an anti-inflammatory substance, a biologically active protein, a substance P antagonist and a muscle relaxant.

### Claim 11 (depends on 10)

The composition of claim 10 wherein said pharmaceutically active substance comprises a non-steroidal anti-inflammatory agent.

### Claim 12 (depends on 2)

The composition of claim 2 comprising lecithin, isopropyl myristate, urea and a surfactant.

### Claim 13 (depends on 12)

The composition of claim 12 comprising lecithin at a concentration of 10-30%, isopropyl myristate at a concentration of 10-30%, urea at a concentration of 5-20%; and a surfactant at a concentration of 10-20% by mass in an aqueous composition.

### Claim 14 (depends on 13)

The composition of claim 13 wherein said aqueous composition comprises about 30% to about 60% water.

### Claim 15 (depends on 10)

The composition, of claim 10 comprising cyclobenzaprine.

### Claim 16 (depends on 2)

The composition of claim 2 comprising about:
10-15% lecithin;
10-15% isopropyl myristate;
10-20% docusate sodium;
5-15% urea;
25- 60% water 25-60%; and
at least one pharmaceutically active ingredient present at between 0.01-30%.

### Claim 17 (depends on 2)

A method of making the composition of claim 2, said method comprising:
(a) dissolving a polar lipid in a pharmaceutically acceptable organic solvent to produce an organic base;
(b) adding at least one surfactant to said organic base said adding producing a surfactant concentration of about 10% to about 20%;
(c) dissolving at least one pharmaceutically active compound in the surfactant mixture of (b);
(d) adding water and (e) adjusting pH to between about 6.0 and about 8.0.

### Claim 18 (depends on 17)

The method of claim 17 wherein said surfactant is added during or after said (d) adding water.

### Claim 19 (depends on 17)

The method of claim 17 further comprising urea to a concentration of about 5% to about 20%.

### Claim 20 (depends on 2)

The composition of claim 2 further comprising a protectant material that solidifies, gels or otherwise remains at the wound surface.

### Claim 21 (depends on 20)

The composition of claim 20 wherein said protectant material is applicable in a spray formulation.

### Claim 22 (depends on 2)

The composition of claim 2 wherein said at least one active ingredient comprises at least one molecule selected from the group consisting of: phyto-cannabinoids, biosimilars and synthetic cannabinoids.
